MNPR Monopar Therapeutics Insider Trading

CFO Vu Quan Anh bought 1,500 shares of MNPR at $69.95; stock now at $65.57, down 35.8% from 52-week high

CFO Vu Quan Anh initiated a position of 1,500 shares at $69.95, representing a first-time purchase with no prior holdings. The acquisition occurs against a backdrop of significant stock weakness: the current price of $65.57 sits 35.8% below the 52-week high of $102.05, and the stock has declined 23.9% over the prior 30 days. The company is unprofitable with net income of $-3,437,601.00 over the most recent full fiscal year, and the latest quarter showed zero revenue. This insider buy by a CFO at a substantially depressed valuation—after steep price declines—presents a potential positive signal regarding management's view of intrinsic value, though the underlying fundamental challenges (negative earnings, no recent revenue) remain material constraints on the transaction's significance.

CEO Chandler Robinson sold 550.2K shares of MNPR at $63.61 for $35.0M, reducing stake by 66.9%

Chandler Robinson, Chief Executive Officer, executed a substantial sale of 550,229 shares at $63.61, reducing his holdings from 822,255 shares to 272,026 shares—a reduction of 66.9% of his pre-transaction position. The $35.0M transaction represents a material liquidation of CEO equity holdings in a single transaction. This large-scale disposition by the company's top executive merits investor scrutiny regarding his commitment to the business and the confidence signaled by retaining only 272,026 shares going forward.

CEO Robinson Chandler sold 16,800 shares (16.8K) of MNPR at $40.00 for $672.0K, reducing stake by 18.6% while company reports $-2.6M net loss and zero revenue.

CEO Robinson Chandler executed a material reduction in MNPR holdings, selling 16,800 shares at $40.00 and retaining 73,472 shares post-transaction. This sale occurred against a backdrop of deteriorating fundamentals: the company reported Revenue $0.00 (latest quarter) and Net income $-2,624,972.00, with negative full-year profitability. The stock is trading -20.8% from its 52-week high of $51.89, suggesting the sale came after significant appreciation yet below peak levels. While the 30-day price movement of +20.0% and 90-day movement of +3.7% indicate recent momentum, the underlying business remains unprofitable with no current-quarter revenue, making visibility into operational recovery limited. Investors should monitor whether this 18.6% reduction in the CEO's stake reflects a broader shift in insider positioning at an unprofitable pre-commercial or early-stage biotech company.

CEO Chandler Robinson sold 33,334 shares of MNPR at $35.00 for $1,166,690.00

Chandler Robinson, Chief Executive Officer, sold 33,334 shares on 2025-04-02 at $35.00, reducing his holdings from 855,589 shares to 822,255 shares. The sale generated $1,166,690.00 and represents a -3.9% reduction in his pre-transaction position. As a CEO with substantial remaining holdings of 822,255 shares, this modest-sized open-market sale warrants standard disclosure monitoring but does not signal abnormal portfolio activity or structural changes in executive positioning.

CFO Radhakrishnan Karthik bought 1,550 shares of MNPR at $16.25 on 2024-10-28 ($25.2K); first purchase for CFO amid unprofitable operations and volatile equity price.

Radhakrishnan Karthik, Chief Financial Officer of Monopar Therapeutics, initiated his first equity stake in the company with a purchase of 1,550 shares at $16.25, bringing his post-transaction holdings to 1,550 shares from zero. The timing is notable: the purchase was made at a price $1.58 above the current market price of $14.67, and at 49.8% of the 52-week high of $32.66, reflecting substantial price decline from peak levels. The stock has experienced extreme volatility—trading -55.1% below its 52-week high while gaining +117.7% over the past 30 days and +323.2% over the past 90 days—suggesting acute near-term fluctuation rather than fundamental stability. Against this backdrop, the CFO's first personal equity purchase is material for governance scrutiny, particularly given that Monopar Therapeutics is currently unprofitable with a net income of $-1.7M and zero revenue in the latest quarter, conditions that typically warrant caution from financial leadership before deploying personal capital.

COO Cittadine Andrew purchased 32,508 shares in 2 transactions at $0.79–$0.86, raising stake to 186,132 shares (+21.2%)

Cittadine Andrew, Chief Operating Officer, executed two separate purchases totaling 32,508 shares for $25,573.85 on June 18 and June 20, 2024, at prices between $0.74 and $0.86. This increased his holdings by 21.2%, from 153,624 to 186,132 shares. The company is currently unprofitable, reporting net income of $-1,641,226.00 over its most recent period and $0.00 in revenue in the latest quarter. The buys occurred within a narrow price band and were part of a cluster of five purchases by this insider at MNPR within the prior two weeks (June 3–17), though the timing outcomes of those earlier trades are not yet measurable. Current trading context shows the stock at $3.45, +12.3% over 30 days but -48.9% from its 52-week high of $6.75.

COO Cittadine Andrew bought 36,000 shares at blended avg $0.91 (2024-06-13 through 2024-06-17) in unprofitable MNPR

Cittadine Andrew, Chief Operating Officer, executed 3 purchases totaling 36,000 shares for $32,894.40, raising his holdings from 117,624 to 153,624 shares (+30.6%). The buys span 2024-06-13 through 2024-06-17 at prices ranging from $0.90 to $0.93, just below Monopar's current price of $4.30 and well below the 52-week high of $6.75. Notably, the insider bought in quick succession across 5 separate transactions at MNPR within the prior two weeks (2024-05-29 through 2024-06-13), signaling sustained accumulation activity. The underlying company is unprofitable, with a negative net income of $-1,641,226.00 over its most recent full fiscal year and zero revenue in the latest quarter, limiting fundamental support for the stock price recovery that has occurred since these purchases.